



## ASX Announcement

18 April 2018

### Creso to Launch Global Beer and Tonic Products with CLV Frontier Brands Joint Venture

#### Highlights:

- **CLV Frontier Brands (“CLV”) to make first sale of beers and tonics this coming Summer in Europe & Canada**
- **CLV is a JV owned by Creso Pharma, LGC Capital and Baltic Beer Company**
- **CLV is developing terpene-based beer and tonic beverages containing the flavour and aroma of cannabis without containing THC, CBD or any other cannabinoids**

**Creso Pharma Limited** (ASX:CPH, the “Company” or “Creso”) is pleased to announce that CLV Frontier Brands Pty Ltd (“CLV”), its equal one-third joint venture with UK-based Baltic Beer Company Ltd and Canadian TSX Venture incorporated LGC Capital, is planning to have its first beers and tonics on sale in Europe and Canada during the summer, with global sales to follow thereafter.

CLV is developing a bespoke and unique range of beers and tonics at its newly-built facilities in Europe, with test brewing well advanced.

Creso is also pleased to announce that the TSX Venture Exchange has conditionally accepted LGC’s joint venture investment in CLV, subject to LGC filing standard documentation with the Exchange.

Dr. Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma stated, “We see CLV as an exciting business partnership that we believe can add significant sales revenues to Creso Pharma over the coming years. Full details of the beer and tonic ranges will be released when CLV debuts its products and branding at a world-wide product launch. Europe will be the initial focus for sales, as Europe is the home market for the Baltic Beer Company’s multi award winning Viru beer. The company also plans to launch in Canada this summer.”

CLV’s beers contain terpenes, which carry the flavour and aroma of cannabis, but which do not contain THC or CBD or any other cannabinoids. The terpenes are extracted from various plant sources, all of which are food-grade, 100% natural and non-genetically modified (GMO) ingredients. The terpenes are pure, not contaminated with any other ingredient, and safe for human consumption as flavouring and food additive ingredients, meeting the criteria of FDA/FEMA GRAS (Generally Recognized as Safe) for human consumption. The terpenes are introduced to the beer at the post-fermentation stage in much the same manner as hop extracts are added.

CLV will have vast commercialisation reach spanning various continents leveraging the networks of all three companies.



#### **About LGC Capital**

**[www.lgc-capital.com](http://www.lgc-capital.com)**

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services with an emphasis on significant investments in global medical cannabis sector.

#### **About Baltic Beer Company Ltd**

**[www.virubeer.com](http://www.virubeer.com)**

A UK based company that created and markets an iconic Estonian beer brand called Viru Premium Estonian Beer. Viru beer is currently sold in numerous markets around the world including Australia, China, UK, Italy and Mexico to name a few and has won multiple awards including gold medals at Monde Selection, Brussels and the World Beer Championships Chicago.

#### **About Creso Pharma**

**[www.cresopharma.com](http://www.cresopharma.com)**

Creso Pharma brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp de-rived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

#### **FORWARD-LOOKING STATEMENTS**

This announcement contains forward-looking statements with respect to Creso and CLV, and their respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward- looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso and CLV could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation. The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and neither Creso nor CLV has any obligation to up-date such statements, except to the extent required by applicable laws.